Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
We studied patients with myeloid neoplasm associated with ringed sideroblasts and/or thrombocytosis. The combination of ringed sideroblasts 15% or greater and platelet count of 450 x 10(9)/L or greater was found in 19 subjects fulfilling the diagnostic criteria for refractory anemia with ringed side...
| Główni autorzy: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
2009
|
| _version_ | 1826295463636107264 |
|---|---|
| author | Malcovati, L Della Porta, MG Pietra, D Boveri, E Pellagatti, A Gallì, A Travaglino, E Brisci, A Rumi, E Passamonti, F Invernizzi, R Cremonesi, L Boultwood, J Wainscoat, J Hellström-Lindberg, E Cazzola, M |
| author_facet | Malcovati, L Della Porta, MG Pietra, D Boveri, E Pellagatti, A Gallì, A Travaglino, E Brisci, A Rumi, E Passamonti, F Invernizzi, R Cremonesi, L Boultwood, J Wainscoat, J Hellström-Lindberg, E Cazzola, M |
| author_sort | Malcovati, L |
| collection | OXFORD |
| description | We studied patients with myeloid neoplasm associated with ringed sideroblasts and/or thrombocytosis. The combination of ringed sideroblasts 15% or greater and platelet count of 450 x 10(9)/L or greater was found in 19 subjects fulfilling the diagnostic criteria for refractory anemia with ringed sideroblasts (RARS) associated with marked thrombocytosis (RARS-T), and in 3 patients with primary myelofibrosis. JAK2 and MPL mutations were detected in circulating granulocytes and bone marrow CD34+ cells, but not in T lymphocytes, from 11 of 19 patients with RARS-T. Three patients with RARS, who initially had low to normal platelet counts, progressed to RARS-T, and 2 of them acquired JAK2 (V617F) at this time. In female patients with RARS-T, granulocytes carrying JAK2 (V617F) represented only a fraction of clonal granulocytes as determined by X-chromosome inactivation patterns. RARS and RARS-T patient groups both consistently showed up-regulation of ALAS2 and down-regulation of ABCB7 in CD34+ cells, but several other genes were differentially expressed, including PSIP1 (LEDGF), CXCR4, and CDC2L5. These observations suggest that RARS-T is indeed a myeloid neoplasm with both myelodysplastic and myeloproliferative features at the molecular and clinical levels and that it may develop from RARS through the acquisition of somatic mutations of JAK2, MPL, or other as-yet-unknown genes. |
| first_indexed | 2024-03-07T04:01:26Z |
| format | Journal article |
| id | oxford-uuid:c4b4496d-4ceb-4c0d-aa9f-921f4f85a4f1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:01:26Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:c4b4496d-4ceb-4c0d-aa9f-921f4f85a4f12022-03-27T06:25:30ZMolecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c4b4496d-4ceb-4c0d-aa9f-921f4f85a4f1EnglishSymplectic Elements at Oxford2009Malcovati, LDella Porta, MGPietra, DBoveri, EPellagatti, AGallì, ATravaglino, EBrisci, ARumi, EPassamonti, FInvernizzi, RCremonesi, LBoultwood, JWainscoat, JHellström-Lindberg, ECazzola, MWe studied patients with myeloid neoplasm associated with ringed sideroblasts and/or thrombocytosis. The combination of ringed sideroblasts 15% or greater and platelet count of 450 x 10(9)/L or greater was found in 19 subjects fulfilling the diagnostic criteria for refractory anemia with ringed sideroblasts (RARS) associated with marked thrombocytosis (RARS-T), and in 3 patients with primary myelofibrosis. JAK2 and MPL mutations were detected in circulating granulocytes and bone marrow CD34+ cells, but not in T lymphocytes, from 11 of 19 patients with RARS-T. Three patients with RARS, who initially had low to normal platelet counts, progressed to RARS-T, and 2 of them acquired JAK2 (V617F) at this time. In female patients with RARS-T, granulocytes carrying JAK2 (V617F) represented only a fraction of clonal granulocytes as determined by X-chromosome inactivation patterns. RARS and RARS-T patient groups both consistently showed up-regulation of ALAS2 and down-regulation of ABCB7 in CD34+ cells, but several other genes were differentially expressed, including PSIP1 (LEDGF), CXCR4, and CDC2L5. These observations suggest that RARS-T is indeed a myeloid neoplasm with both myelodysplastic and myeloproliferative features at the molecular and clinical levels and that it may develop from RARS through the acquisition of somatic mutations of JAK2, MPL, or other as-yet-unknown genes. |
| spellingShingle | Malcovati, L Della Porta, MG Pietra, D Boveri, E Pellagatti, A Gallì, A Travaglino, E Brisci, A Rumi, E Passamonti, F Invernizzi, R Cremonesi, L Boultwood, J Wainscoat, J Hellström-Lindberg, E Cazzola, M Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| title | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| title_full | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| title_fullStr | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| title_full_unstemmed | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| title_short | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| title_sort | molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis |
| work_keys_str_mv | AT malcovatil molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT dellaportamg molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT pietrad molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT boverie molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT pellagattia molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT gallia molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT travaglinoe molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT briscia molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT rumie molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT passamontif molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT invernizzir molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT cremonesil molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT boultwoodj molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT wainscoatj molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT hellstromlindberge molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis AT cazzolam molecularandclinicalfeaturesofrefractoryanemiawithringedsideroblastsassociatedwithmarkedthrombocytosis |